Useful link

Setting up in Lyon with help from ADERLY

Become a partner

Sanoﬁ Pasteur is interested in partners who will share our pursuit of innovation and our drive for excellence, while becoming a part of our market success story. We welcome the opportunity to evaluate technologies related to the development and production of human vaccines, both prophylactic and therapeutic, including vaccines for infectious and chronic diseases.

Sanoﬁ Pasteur has a strong commitment to Research and Development partnerships with major universities, research institutes, government bodies, biotechnology companies and contract research organizations. Our collaborations cover virtually all aspects of vaccine development, including early-stage research.

Examples of current partnerships and technology investments include: vaccines for dengue fever, Japanese encephalitis, S. pneumoniae, N. meningitidis B, and M. tuberculosis; pediatric combination vaccines; rabies monoclonal antibodies; large-scale, cell culture-based virus production; adjuvants and immunomodulators; conjugate vaccine production; and vaccine delivery systems.

When partnering with sanoﬁ pasteur, you will interact with a multidisciplinary team that has years of experience in working to ensure that partnerships are executed succesfully and nurtured for the mutual beneﬁt of all parties.
This approach utilizes the value-added sanoﬁ pasteur alliance management capability, which focuses on the relationship by facilitating open communication trust, understanding and clear expectations across the project lifespan. Combined with the technical competency of the alliance, this balance provides a wellrounded environment for your technology to ﬂourish.

Partnership Opportunities

Sanoﬁ Pasteur is interested in potential partnering opportunities in the ﬁeld of active and passive human immunization, including:

Vaccines, monoclonal antibodies and supporting technologies for prevention and treatment of infectious diseases

Novel antigens for vaccine development

Monoclonal antibodies, including antigens as targets for monoclonal antibody development

Antigen discovery and characterization

Carrier proteins and protein-polysaccharide conjugation methods or alternative technologies

Agents to enhance vaccine immune responses – such as adjuvants and immunomodulators

Adjuvants, particularly those that drive Th1 and Th2 immune responses

Vaccine vectors intended to enhance or modify immune responses

Characterization, modulation and assay of protective imune responses

Areas of basic immunology applicable to vaccine development, such as studies of innate immunity, immune escape mechanisms, and immunoregulation

New vaccine delivery systems

New ways to administer vaccines

Vaccine vectors suitable for nasal or oral use

Tools for improving vaccine and monoclonal antibody research, development and production

Animal models of human diseases

Development and application of new technologies in the areas of genomics and proteomics

Bioinformatics techniques for data handling and analysis

Prokaryotic or eukaryotic cell lines for antigen production

Fermentor and bioreactor technology

Downstream processing and puriﬁcation processes

Preservatives and stabilizers

Identiﬁcation of biological markers for evaluating the efﬁcacy of prophylactic or therapeutic interventions for infectious diseases

Epidemiological studies relevant to the use of vaccines and immunotherapeutics